
211: Biotech's catch-22, a $100 genome, & dealing with monkeypox
The Readout Loud
00:00
Biotec Index
In the past few months, we've seen what appears to be positive data from various companies be rewarded. But with nearly a thousand companies in in the public realm, and many that are private, those same data points have diminishing marginal return. Investors are much more sceptical that these data sets, in isolation, are going to have a big impact. We have to get to a point where there is actually less asset or stock selection to be had. And that would be that would come in the form of mergers with respect to the small and micro cabiote community. Once we get to that point, then i think the dhis sector can actually work.
Transcript
Play full episode